Controversy Surrounds Gene Therapy Effort

A key experiment has been approved, but many researchers worry that slipping genes into humans is premature. BETHESDA, MD.--Maybe W. French Anderson wouldn't be in the center of a slow-burning controversy if it weren't for the letters. But he can't escape them. Several times a week, new correspondence lands on his desk on the seventh floor of Building 10 at the National Institutes of Health in Bethesda. The letters come from all across the United States and from dozens of foreign countries, a

Written byRobert Buderi
| 8 min read

Register for free to listen to this article
Listen with Speechify
0:00
8:00
Share

BETHESDA, MD.--Maybe W. French Anderson wouldn't be in the center of a slow-burning controversy if it weren't for the letters. But he can't escape them. Several times a week, new correspondence lands on his desk on the seventh floor of Building 10 at the National Institutes of Health in Bethesda. The letters come from all across the United States and from dozens of foreign countries, and they are all heartrending. Written by the friends, families, and physicians of those stricken with genetic illness, they ask one question: When will gene therapy live up to its promise to cure genetic ills?

Motivated by scientific curiosity and ambition as well as by these appeals, Anderson is searching passionately for an answer. He wants to forge ahead with his research by actually inserting new genes into people. But some scientists worry that the chief of the National Heart, Lung and Blood Institute's Laboratory ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies